Expression of p21WAF1, p27KIP1 and cyclin E in ameloblastoma.
- Author:
Ming ZHONG
1
;
Jie LIU
;
Yan-bing GONG
;
Jing-dong LIU
;
Jie WANG
;
Bo ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Ameloblastoma; metabolism; pathology; Child; Cyclin E; genetics; metabolism; Cyclin-Dependent Kinase Inhibitor p21; genetics; metabolism; Cyclin-Dependent Kinase Inhibitor p27; Female; Humans; Intracellular Signaling Peptides and Proteins; genetics; metabolism; Jaw Neoplasms; metabolism; pathology; Middle Aged; Oncogene Proteins; genetics; metabolism; RNA, Messenger; genetics; metabolism; Young Adult
- From: Chinese Journal of Stomatology 2005;40(4):306-309
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression of cyclin E mRNA, p21(WAF1) mRNA and p27(KIP1) protein in human ameloblastoma (AB), and to explore the clinical and biological characteristics of AB.
METHODSThe expression of cyclin E mRNA, p21(WAF1) mRNA and p27(KIP1) protein in 54 cases of human AB were detected by in situ hybridization or immunohistochemistry (SP method).
RESULTSThe positive expression rate of cyclin E mRNA in the cytoplasm or cell nucleus of AB was 66.7% (36/54). The expression of cyclin E mRNA increased with AB recurrence and malignant transformation, and the difference of expression among primary AB, recurrent AB, and malignant AB, was statistically significant. The positive expression ratio of cyclin E mRNA in OKC was 50.0% (8/16). The p21(WAF1) mRNA expression in the cytoplasm or cell nucleus of AB decreased, and the positive ratio was 22.6% (12/54) in AB, 37.5% (6/16) in OKC, respectively. The p27(KIP1) protein expression in the cell nucleus of AB was positive in a small number of cases, and the positive rate was 16.7% (9/54) in AB, 6.3% (1/16) in OKC, respectively.
CONCLUSIONSThe genesis and invasion of AB is associated with the cell proliferation and differentiation, and regulated by the higher expression of cyclin E and the lower expression of p21(WAF1) and p27(KIP1).
